New Treatment Offers Hope for Hardest-to-Treat Hepatitis C Patients
WebMD News Archive
It is estimated that four million people in the United States are chronically infected with hepatitis C, and as many as 70% will develop liver disease caused by the virus. Worldwide, some 170 million people are infected with hepatitis C. Infection can lead to cirrhosis, liver cancer, and liver failure and is the most common reason for liver transplants in the U.S. today.
Because symptoms do not generally develop until a decade or more after infection, many people who have chronic hepatitis C don't realize it.
In the study reported by Brillanti and colleagues, 40 patients were treated with the triple-drug therapy containing amantadine, and 20 patients received the interferon and ribavirin combination only. The patients received therapy for one year.
Almost half of the patients treated with the triple-drug therapy had sustained responses to treatment six months after its completion, compared with just 5% of patients treated with the interferon and ribavirin combo alone. At one year after the end of therapy, almost 40% of the responding patients given the three-drug regimen had not relapsed, Brillanti says.
The Italian researchers are now testing the three-drug regimen in a group of 500 patients who failed initial therapy with the interferon and ribavirin combination. They published the results of this study in the Sept. issue of the journal, Hepatology.
"We were very skeptical before we saw how well this worked, but we now believe amantadine may act synergistically with interferon and ribavirin. We aren't exactly sure how, but we think it is very exciting."
Eugene R. Schiff, MD, of the University of Miami (Fla.) Center for Liver Disease, says he remains skeptical about the usefulness of the three-drug combination therapy, although he quickly adds that he hopes the Italian findings are confirmed. His center is currently using the regimen in some patients, as are others around the U.S., and he says more data will certainly be available within a year. Schiff, a spokesman for the American Association for the Study of Liver Disease, reviewed the study for WebMD.
Despite past disappointments, Vogel says she is still willing to try new therapies in an effort to keep her disease from progressing. She has enrolled in a University of Southern California study evaluating a novel form of interferon known as PEGASYS given with ribavirin.
She remains optimistic but says she is also angry that there are so few treatment options for patients with chronic hepatitis C.
"We are really at the point where HIV was 15 years ago," she says. "We are just beginning and there is not much out there. This is an epidemic, but the government doesn't seem to understand that there are more people with hepatitis C than there are with AIDS. We need the same kind of effort to find new therapies." -->